A scientific illustration representing medical research and cancer treatment trials in a laboratory setting.
Health

Daraxonrasib Pill Trial Hailed as Major Breakthrough for Pancreatic Cancer

Illustration: NexVani Media

By: NexVani DeskDate: 20 November 2026Views: 0

A new pill trial shows remarkable results in advanced pancreatic cancer patients, halting tumour growth and making the disease undetectable in some.

A novel medication is being celebrated as a major advance in oncology following a clinical trial for individuals recently diagnosed with advanced pancreatic cancer. The drug, daraxonrasib, demonstrated significant potential in shrinking and potentially eliminating pancreatic tumours during testing involving sixty-one participants whose disease had spread to other parts of the body.

During the trial, tumours stopped growing in ninety percent of the participants, while over sixty percent experienced shrinkage or complete disappearance of their growths. For approximately eight percent of the individuals involved, the disease became entirely undetectable on computed tomography scans. Patients were monitored for an average of a year and a half, with some seeing no recurrence during this period. Furthermore, seventy-six point six percent of individuals were still alive one year after beginning the treatment.

Daraxonrasib trial halts pancreatic cancer growth and makes disease undetectable for some patients.

Dr Wungki Park of the Memorial Sloan Kettering Cancer Center presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. He noted that the outcomes represent the closest observed instance to a complete cure in cases where the disease has spread. The therapy functions as a KRAS inhibitor by binding to and shutting down specific mutations that drive tumour progression in the majority of pancreatic malignancies. This mechanism has raised optimism that the approach could eventually be adapted to address numerous other malignancies carrying comparable genetic changes.

Medical Community Reacts to New Pill Treatment for Cancer

Although medical professionals emphasize that the medication cannot yet be classified as a definitive cure and the duration of disease control remains uncertain, the results provide considerable encouragement. Standard chemotherapy typically yields a one-year survival rate of forty to forty-five percent, whereas the new trial indicates improved outcomes and a near doubling of disease control duration. Michelle Mitchell, chief executive of Cancer Research UK, described the development as the most significant advancement witnessed in decades for this specific illness, though she stressed that additional clinical evaluations are required before the therapy can be evaluated for standard healthcare system implementation.

Why it matters

Pancreatic cancer possesses one of the lowest survival rates among common malignancies, with half of all diagnosed individuals dying within three months and only about three percent surviving for five years after metastasis. This trial offers renewed hope for patients facing one of the most challenging diagnoses in modern medicine, potentially paving the way for extended survival and future treatments targeting similar genetic mutations globally.

Add NexVani Media as a preferred source on Google

Sources

ND

NexVani Desk

NexVani Media brings you the most important world news as it happens, with every story linked to its sources.